IKZF3 and gastric cancer: Ultimately, we conducted a comprehensive analysis of the prognosis in GC patients with co-amplification of IKZF3 and HER2, and significant reductions were observed in both DFS and OS among all 404 GC patients (Fig. 4A-B) as well as IGC patients (Fig. 4C-D).